CDP7657

BIOLOGICAL2 trials

Sponsors

UCB Pharma

Conditions

Autoimmune DiseasesConnective Tissue DiseaseImmune System DiseasesLupus Erythematosus, SystemicSkin and Connective Tissue Diseases

Phase 1

Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

CompletedNCT01093911

UCB PharmaAutoimmune Diseases, Connective Tissue Disease, Immune System Diseases +2

Start: 2010-03-31End: 2012-12-31Updated: 2013-01-04

Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

CompletedNCT01764594

UCB PharmaAutoimmune Diseases, Connective Tissue Disease, Immune System Diseases +2

Start: 2013-01-31End: 2014-08-31Updated: 2015-07-16

Related Papers

Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.

2017-08-0577 citations

90 Safety, efficacy and transcriptional changes following repeated administration of dapirolizumab pegol in patients with systemic lupus erythematosus: results from a phase i study

2017-03-01